This is a working overview of pharmacokinetics, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Ethnic tensions created during colonial occupation also resulted in discriminatory policies being adopted in newly independent African nations, such as Uganda under Idi Amin which banned Asians from Uganda, thus creating a mass exodus of the (largely Gujarati) Asian community of Uganda. Such ethnically driven border control policies took forms ranging from anti-Asian sentiment in East Africa to Apartheid policies in South Africa and Namibia (then known as Southwest Africa under South African rule) which created bantustans and pass laws to segregate and impose border controls against non-whites, and encouraged immigration of whites at the expense of Blacks as well as Indians and other Asians. Whilst border control in Europe and east of the Pacific have tightened over time, they have largely been liberalized in Africa, from Yoweri Museveni's reversal of Idi Amin's anti-Asian border controls to the fall of Apartheid (and thus racialized border controls) in South Africa. With the development of border control policies over the course of the 20th century came the standardization of refugee travel documents under the Convention Relating to the Status of Refugees of 1951 and the 1954 Convention travel document for stateless people under the similar 1954 statelessness convention.
Heterologous vaccines also known as "Jennerian vaccines", are vaccines that are pathogens of other animals that either do not cause disease or cause mild disease in the organism being treated. The classic example is Jenner's use of cowpox to protect against smallpox. A current example is the use of BCG vaccine made from Mycobacterium bovis to protect against tuberculosis.
== Further reading == A. Abragam (1961). The Principles of Nuclear Magnetism. Clarendon Press. ISBN 978-0-19-852014-6. {{cite book}}: ISBN / Date incompatibility (help) J.W. Akitt; B.E. Mann (2000). NMR and Chemistry. Cheltenham, UK: Stanley Thornes. pp. 273, 287. ISBN 978-0-7487-4344-5. K.V.R. Chary, Girjesh Govil (2008) NMR in Biological Systems: From Molecules to Human. Springer. ISBN 978-1-4020-6680-1. G.M. Clore; A.M. Gronenborn (1991). "Structures of larger proteins in solution: three- and four-dimensional heteronuclear NMR spectroscopy". Science. 252 (5011): 1390–1399. Bibcode:1991Sci...252.1390M. doi:10.1126/science.2047852. OSTI 83376. PMID 2047852. John Emsley; James Feeney; Leslie Howard Sutcliffe (1965). High Resolution Nuclear Magnetic Resonance Spectroscopy. Pergamon. ISBN 978-1-4831-8408-1. The Feynman Lectures on Physics Vol. II Ch. 35: Paramagnetism and Magnetic Resonance David M. Grant; Robin Kingsley Harris (2002). "Advances in NMR". Encyclopedia of Nuclear Magnetic Resonance. John Wiley. ISBN 978-0-471-49082-1. R.L. Haner; P.A. Keifer (2009). "Flow Probes for NMR Spectroscopy". Encyclopedia of Magnetic Resonance. John Wiley. doi:10.1002/9780470034590.emrstm1085. ISBN 978-0-470-03459-0. J.P. Hornak. "The Basics of NMR". Retrieved 23 February 2009. J. Keeler (2005). Understanding NMR Spectroscopy. John Wiley & Sons. ISBN 978-0-470-01786-9. Gary E. Martin; A. S. Zektzer (1988). Two-Dimensional NMR Methods for Establishing Molecular Connectivity. New York: Wiley-VCH. p. 59. ISBN 978-0-471-18707-3. J.A.Pople; W.G.Schneider; H.J.Bernstein (1959).
Arterial bypass surgery to create another source of blood supply Embolectomy, to remove the embolus, with various techniques available: Thromboaspiration Angioplasty with balloon catheterization with or without implanting a stent Balloon catheterization or open embolectomy surgery reduces mortality by nearly 50% and the need for limb amputation by approximately 35%. Embolectomy by open surgery on the artery If extensive necrosis and gangrene has set in an arm or leg, the limb may have to be amputated. Limb amputation is in itself usually remarkably well-tolerated, but is associated with substantial mortality (~50%), primarily because of the severity of the diseases in patients where it is indicated.
==== Withdrawn ==== Amanda Edwards, former at-large Houston city councilor (2016–2020), candidate for U.S. Senate in 2020, candidate for this district in 2024, and runner-up in the 2025–26 special election (remained on ballot)
Sources: en.wikipedia.org
=== Intravenous administration === Many forms of medication (from antibiotics to chemotherapy) are administered intravenously, as they are not readily or adequately absorbed by the digestive tract. After severe acute blood loss, liquid preparations, generically known as plasma expanders, can be given intravenously, either solutions of salts (NaCl, KCl, CaCl2 etc.) at physiological concentrations, or colloidal solutions, such as dextrans, human serum albumin, or fresh frozen plasma. In these emergency situations, a plasma expander is a more effective life-saving procedure than a blood transfusion, because the metabolism of transfused red blood cells does not restart immediately after a transfusion.
It is most likely that the new allele will be non-functional—in which case it will probably result in low fitness and be removed from the population by natural selection. Alternatively, if the amino acid residue that is changed is in a relatively unimportant part of the enzyme (e.g., a long way from the active site), then the mutation may be selectively neutral and subject to genetic drift. In rare cases, the mutation may result in an enzyme that is more efficient, or one that can catalyse a slightly different chemical reaction, in which case the mutation may cause an increase in fitness, and be favoured by natural selection.
Inoculation and fermentation: Skimmed milk is pumped into enclosed vats and heated to approximately 30–32 °C (86–90 °F). A mesophilic starter culture of lactic acid-producing strains (such as Lactococcus lactis ssp. lactis or L. lactis ssp. cremoris) is introduced. These bacteria ferment the milk's lactose into lactic acid, dropping the pH over 4 to 8 hours. Coagulation: A precise dose of microbial or animal rennet is added to facilitate protein cross-linking. The rising acidity and the rennet cause the milk to curdle into a uniform, gelatinous mass. Cutting and cooking: Internal wire grids slice the gel into uniform cubes, determining whether the batch is classified as "small-curd" (<4 mm) or "large-curd" (>8 mm). The vats are heated to 49–54 °C (120–130 °F) under gentle agitation, causing the curd to contract and expel liquid whey. Washing and dressing: The whey is drained, and the curd mass is flooded with chilled, purified water. This stops further bacterial acidification and rinses away excess lactic acid, resulting in a mild flavour profile. The dry curds are then mechanically blended with a pasteurised cream dressing and salt.
Class I: Severe deficiency (<10% activity) with chronic (nonspherocytic) hemolytic anemia Class II: Severe deficiency (<10% activity), with intermittent hemolysis Class III: Moderate deficiency (10–60% activity), hemolysis with stressors only Class IV: Non-deficient variant, no clinical sequelae Class V: Increased enzyme activity, no clinical sequelae
Sources: en.wikipedia.org
Myofascial pain syndrome (MPS), also known as chronic myofascial pain (CMP), is a syndrome characterized by chronic pain in multiple myofascial trigger points ("knots") and fascial (connective tissue) constrictions. It can appear in any body part. Symptoms of a myofascial trigger point include: focal point tenderness, reproduction of pain upon trigger point palpation, hardening of the muscle upon trigger point palpation, pseudo-weakness of the involved muscle, referred pain, and limited range of motion following approximately 5 seconds of sustained trigger point pressure. The cause is believed to be muscle tension or spasms within the affected musculature. However, emerging evidence suggests that fascial tissue and its biomechanical and neurophysiological properties may also contribute to the development and persistence of myofascial pain. Diagnosis is based on the symptoms and possible sleep studies. Treatment may include pain medication, physical therapy, mouth guards, and occasionally benzodiazepine. It is a relatively common cause of temporomandibular pain.
WCU and the EBCI have initiated a ten-year language revitalization plan consisting of: (1) a continuation of the improvement and expansion of the EBCI Atse Kituwah Cherokee Language Immersion School, (2) continued development of Cherokee language learning resources, and (3) building a Western Carolina University programs to offer a more comprehensive language training curriculum. On November 30, 2020, the Cherokee Nation unveiled plans for the new Durbin Feeling Language Center, a converted casino that will house all of the tribe's language programs under one roof in Tahlequah. The project includes five nearby houses in which native speakers will be invited to live, to facilitate interaction between native speakers and others at the facility.
Duncan returns to the mansion, where the few remaining henchmen flee rather than face him. Now alone, Blut awaits Duncan but ends up decapitated while calling for someone to bring him Camille. Rescuing Camille, Duncan returns to Montana and treats her inside her cabin. Duncan awakens one morning inside the cabin to find newspaper clippings of the murder of a family spread around Camille's bed. He recognizes the images as a hit that he carried out, albeit with bad intel, something that has haunted him ever since. The only survivor of the family was a daughter, who grew up to be Camille. To assuage his guilty conscience he has been making anonymous donations to her ever since, and she tracked him down by following the money trail. Held at gunpoint by Camille, Duncan apologizes and tells her to close her mind and pull the trigger. However, she spares him, asking if they can determine who ordered her father dead, and he commits to help her.
A reliable means of propulsion for the submerged vessel was only made possible in the 1880s with the advent of the necessary electric battery technology. The first electrically powered boats were built by Isaac Peral y Caballero in Spain (who built Peral), Dupuy de Lôme (who built Gymnote) and Gustave Zédé (who built Sirène) in France, and James Franklin Waddington (who built Porpoise) in England. Peral's design featured torpedoes and other systems that later became standard in submarines.
The nitrate is usually white but can be brown due to radiolytic decomposition. Heating the nitrate in air at 400 °C converts it to the white protactinium pentoxide. The polytrioxophosphate Pa(PO3)4 can be produced by reacting the difluoride sulfate PaF2SO4 with phosphoric acid (H3PO4) under an inert atmosphere. Heating the product to about 900 °C eliminates the reaction by-products, which include hydrofluoric acid, sulfur trioxide, and phosphoric anhydride. Heating it to higher temperatures in an inert atmosphere decomposes Pa(PO3)4 into the diphosphate PaP2O7, which is analogous to diphosphates of other actinides. In the diphosphate, the PO3 groups form pyramids of C2v symmetry. Heating PaP2O7 in air to 1400 °C decomposes it into the pentoxides of phosphorus and protactinium.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.